Troikka Pharmaceuticals Managing Director Ketan Patel said, ''Our focus has been to address unmet medical needs through innovative drug delivery. The introduction of Dynapar AQ in 1 ml dose is in line with our promise to provide technology that augments existing healthcare treatments.'' Mr Patel said that currently available diclofenac injections administered in the buttock deliver 75 mg diclofenac in three ml which is large in volume and causes muscle damage in the injected area, while Dynapar AQ delivers the full dose in just one ml and can be conveniently administered in the arm causing minimum muscle damage and pain.
Dynapar manufactured by the Aquatech Process is the world's only diclofenac injection that can be injected in the arm as well as intra gluteal route, Mr Patel claimed.
It becomes especially advantageous to overweight patients, who have thick layers of fat in the buttock region, as this fat hampers the absorption of the injected dose resulting in inadequate efficacy of the presently available diclofenac injections, he said.
Before the market launch, the product has been gone through several clinical trials at reputed hospitals including Sir J J Hospital in Mumbai, Max Superspeciality Hospital in New Delhi, V S Hospital in Ahmedabad and Sancheti Institute for Orthopaedics and rehabilitation in Pune.
All clinical trials have established that Dynapar AQ is well tolerable by patients of both genders and is painless. With the launch of Dynapar AQ, Troikaa Pharmaceuticals has extended its global patent application to over 107 countries, he added.